6.80
0.0575
100000000
4200000
90000000
20000000
90000000
20000000
0.0875
0.0975
0.25
5.00
60000000
12000000
2900000
0.119
388615163
20000000
0.0975
160000000
160000000
40000000
90000000
2900000
9000000
28005000
386934914
0.01
9000000
550000000
0.01
10000000
386934914
9000000
958000
44515000
-4000
6650000
113582000
5724000
3638000
14319000
17536000
25871000
2362129000
30100000
15006000
98662000
49521000
207017000
1300000
370000
3869000
224553000
8437000
34900000
289919000
380000
176337000
224553000
35759000
2348458000
3640000
39399000
1304000
13393000
10000000
380000
9000000
8078000
120000000
40000000
25000000
40000000
40000000
3656000
2921000
90000000
4580000
0.0584
30100000
1300000
49500000
14000000
9900000
3700000
107000
0.0575
100000000
98662000
95100000
1000000
1338000
25871000
120000000
25900000
25700000
92500000
1546000
83000
3151000
16276000
13013000
51000
61000
114099000
17041000
82189000
54948000
5273000
17000
11306000
5046000
61840000
369391972
0.01
550000000
0.01
10000000
369391972
2082000
127794000
-4000
12193000
111060000
5706000
3860000
13605000
-30713000
102300000
2261996000
21634000
98439000
49521000
289359000
342000
3697000
258646000
5516000
67700000
287617000
298000
176557000
258646000
70790000
2296402000
5485000
76275000
1311000
298000
9000000
100000000
98439000
102200000
2400000
1561000
102300000
107000000
114099000
14756000
82189000
54948000
5273000
17000
11289000
5046000
147.0859
P30D
20
1.00
1.50
1000
1.50
0.3333
1.50
0.3333
2019-12-31
1500000
7500000
10763829
60000000
4
0.125
0.127
350000000
370000000
2020-01-05
6559251
33500000
-1761983000
-1761983000
3166000
337142000
92500000
-1237000
48000
26000
598000
37005000
2758000
230000
796779000
115000000
-2371670000
1667000
1700000
-8792000
77282000
17861000
-2348840000
1690000
-2348462000
-1101000
-2272077000
-990000
70000000
1028000
-2348458000
-4000
-4000
3331000
22105000
2134816000
5248000
3460000
500615000
952000
194042000
150228000
35759000
-337074000
15000000
59128000
2275243000
207050000
-382000
1742000
96085000
2309000
3900000
454000
1603474000
119500000
1303000
4220000
22260000
387750000
19726000
151428000
796393000
48000
45848000
32019000
6494000
50000000
191000
-25070000
2949000
1921000
3018000
623000
290334000
4296000
-379000
28080000
29317000
171154000
50000000
1451640000
2921000
15000000
50000000
-32027000
280058000
133500568
-0.15
1459000
1000
-40965000
3863000
23000
2863000
427000
-40965000
-690000
-40967000
2000
-36437000
0
-40965000
-2000
-2000
-349000
10039000
209000
5189000
3348000
-33835000
-1459000
2863000
36437000
-924000
26398000
2990000
5189000
0
1689000
715000
-78000
78000
MNKD
MANNKIND CORP
false
Large Accelerated Filer
2014
10-Q
2014-03-31
0000899460
--12-31
Q1
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The following is a summary of the carrying values and estimated
fair values of the Company’s 5.75% Senior Convertible Notes
due 2015 (the “2015 notes”) and the 2019 notes (in
millions).</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
<tr>
<td width="66%"></td>
<td valign="bottom" width="5%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="5%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="5%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="5%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>March 31, 2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December 31, 2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Carrying<br />
value</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Estimated<br />
fair value</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Carrying<br />
value</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Estimated<br />
fair value</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
2015 notes</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">98.7</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">95.1</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">98.4</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">102.2</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
2019 notes</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">25.9</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">25.7</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">102.3</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">107.0</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
</table>
</div>
<div>
<p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Property and equipment — net consist of the following (dollar
amounts in thousands):</p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 </p>
<table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
<tr>
<td width="68%"></td>
<td valign="bottom" width="5%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="5%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="5%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="font-family:Times New Roman; font-size:8pt">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Estimated<br />
Useful<br />
Life<br />
(Years)</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>March 31,<br />
2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>December 31,<br />
2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Land</p>
</td>
<td valign="bottom">  </td>
<td nowrap="nowrap" valign="bottom"> </td>
<td nowrap="nowrap" valign="bottom" align="right">
—  </td>
<td nowrap="nowrap" valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">5,273</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">5,273</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Buildings</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">39-40</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">54,948</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">54,948</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Building improvements</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">5-40</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">114,099</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">114,099</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Machinery and equipment</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">3-15</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">82,189</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">82,189</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Furniture, fixtures and office equipment</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">5-10</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">5,046</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">5,046</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Computer equipment and software</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">3</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">11,306</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">11,289</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Leasehold improvements</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">4</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">17</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">17</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Construction in progress</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">17,041</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">14,756</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-size:1px;">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top"></td>
<td valign="bottom"><font style="font-size:8pt">  </font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font style="font-size:8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">289,919</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"><font style="font-size:8pt"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">287,617</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Less accumulated depreciation and amortization</p>
</td>
<td valign="bottom"><font style="font-size:8pt">  </font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font style="font-size:8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(113,582</td>
<td nowrap="nowrap" valign="bottom">) </td>
<td valign="bottom"><font style="font-size:8pt"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(111,060</td>
<td nowrap="nowrap" valign="bottom">) </td>
</tr>
<tr style="font-size:1px;">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Property and equipment — net</p>
</td>
<td valign="bottom"><font style="font-size:8pt">  </font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font style="font-size:8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">176,337</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"><font style="font-size:8pt"> </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">176,557</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-size:1px;">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td> </td>
</tr>
</table>
</div>
<div>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<b>6. Property and equipment</b></p>
<p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Property and equipment — net consist of the following (dollar
amounts in thousands):</p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 </p>
<table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
<tr>
<td width="68%"></td>
<td valign="bottom" width="5%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="5%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="5%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="font-family:Times New Roman; font-size:8pt">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Estimated<br />
Useful<br />
Life<br />
(Years)</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>March 31,<br />
2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>December 31,<br />
2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Land</p>
</td>
<td valign="bottom">  </td>
<td nowrap="nowrap" valign="bottom"> </td>
<td nowrap="nowrap" valign="bottom" align="right">
—  </td>
<td nowrap="nowrap" valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">5,273</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">5,273</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Buildings</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">39-40</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">54,948</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">54,948</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Building improvements</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">5-40</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">114,099</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">114,099</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Machinery and equipment</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">3-15</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">82,189</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">82,189</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Furniture, fixtures and office equipment</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">5-10</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">5,046</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">5,046</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Computer equipment and software</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">3</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">11,306</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">11,289</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Leasehold improvements</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">4</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">17</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">17</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Construction in progress</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">17,041</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">14,756</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-size:1px;">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top"></td>
<td valign="bottom"><font style="font-size:8pt">  </font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font style="font-size:8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">289,919</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"><font style="font-size:8pt"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">287,617</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Less accumulated depreciation and amortization</p>
</td>
<td valign="bottom"><font style="font-size:8pt">  </font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font style="font-size:8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(113,582</td>
<td nowrap="nowrap" valign="bottom">) </td>
<td valign="bottom"><font style="font-size:8pt"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(111,060</td>
<td nowrap="nowrap" valign="bottom">) </td>
</tr>
<tr style="font-size:1px;">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Property and equipment — net</p>
</td>
<td valign="bottom"><font style="font-size:8pt">  </font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font style="font-size:8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">176,337</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"><font style="font-size:8pt"> </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">176,557</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-size:1px;">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td> </td>
</tr>
</table>
<p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Leasehold improvements are amortized over four years which is the
shorter of the term of the lease or the service lives of the
improvements.</p>
<p style="font-size:1px;margin-top:12px;margin-bottom:0px">
 </p>
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Depreciation and amortization expense related to property and
equipment for the three months ended March 31, 2014 and 2013
was as follows (in thousands):</p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 </p>
<table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" align="center">
<tr>
<td width="82%"></td>
<td valign="bottom" width="4%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="4%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="font-family:Times New Roman; font-size:8pt">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">
<b>Three months ended<br />
March 31,</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="font-family:Times New Roman; font-size:8pt">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Depreciation and amortization expense</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">2,522</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">2,990</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-size:1px;">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td> </td>
</tr>
</table>
</div>
<div>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 18pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
<b>11. Facility financing agreement</b></p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 6pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
The components and activity from initial recording of the facility
financing agreement recorded through March 31, 2014 consist of
the following (in thousands):</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 0pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 12pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
 </p>
<table style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; LETTER-SPACING: normal; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; WORD-SPACING: 0px; -webkit-text-stroke-width: 0px" border="0" cellspacing="0" cellpadding="0" width="68%" align="center">
<tr>
<td width="87%"></td>
<td valign="bottom" width="6%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>March 31,<br />
2014</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
<b>2019 notes</b></p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<td valign="top">
<p style="TEXT-INDENT: -1em; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
Initial principal amount</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">120,000</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
Principal converted to equity</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(92,500</td>
<td valign="bottom" nowrap="nowrap">) </td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<td valign="top">
<p style="TEXT-INDENT: -1em; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
Debt discount-net of amortization</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(1,546</td>
<td valign="bottom" nowrap="nowrap">) </td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
Unaccreted debt issuance expense</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(83</td>
<td valign="bottom" nowrap="nowrap">) </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<td valign="top">
<p style="TEXT-INDENT: -1em; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
Net carrying amount of facility financing agreement</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">25,871</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td> </td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
<b>Milestone Rights</b></p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<td valign="top">
<p style="TEXT-INDENT: -1em; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
Initial milestone rights fair value</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">16,276</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
Debt discount-net of amortization</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(51</td>
<td valign="bottom" nowrap="nowrap">) </td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<td valign="top">
<p style="TEXT-INDENT: -1em; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
Unaccreted debt issuance expense</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(61</td>
<td valign="bottom" nowrap="nowrap">) </td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
Less current portion of milestone rights included in other current
liabilities</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(3,151</td>
<td valign="bottom" nowrap="nowrap">) </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<td valign="top">
<p style="TEXT-INDENT: -1em; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
Net carrying amount included in other liabilities</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">13,013</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td> </td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
<b>Commitment Asset</b></p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<td valign="top">
<p style="TEXT-INDENT: -1em; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
Initial commitment asset fair value</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">13,393</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
Tranche B commitment asset fair value</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">2,921</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<td valign="top">
<p style="TEXT-INDENT: -1em; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
Less Tranche 2 portion of commitment asset</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(3,656</td>
<td valign="bottom" nowrap="nowrap">) </td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
Less Tranche 3 portion of commitment asset</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(4,580</td>
<td valign="bottom" nowrap="nowrap">) </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<td valign="top">
<p style="TEXT-INDENT: -1em; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
Commitment asset value included in other assets</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">8,078</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td> </td>
</tr>
</table>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
Accretion of debt issuance cost and debt discount in connection
with the Facility financing agreement during the three months ended
March 31, 2014 are as follows (in thousands):</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 0pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 12pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
 </p>
<table style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; LETTER-SPACING: normal; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; WORD-SPACING: 0px; -webkit-text-stroke-width: 0px" border="0" cellspacing="0" cellpadding="0" width="68%" align="center">
<tr>
<td width="78%"></td>
<td valign="bottom" width="17%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Three months ended<br />
March 31, 2014</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
Accretion expense- debt issuance cost</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">282</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<td valign="top">
<p style="TEXT-INDENT: -1em; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
Accretion expense- debt discount</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">6,367</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
</table>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
On July 1, 2013, the Company entered into the Facility
Agreement providing for the sale of up to $160.0 million of
2019 notes to Deerfield in four equal tranches of $40.0 million
principal amount. The 2019 notes accrue interest at a rate of
9.75% per annum until maturity in 2019 or their earlier
repayment, repurchase, or conversion. As of March 31, 2014,
Deerfield had purchased the first three tranches of 2019 notes in
the aggregate principal amount of $120.0 million; therefore, only
$40.0 million remain unsold. Deerfield’s obligation to
purchase the fourth tranche of 2019 notes is subject to receipt of
marketing approval of AFREZZA by the FDA and the shares of common
stock issuable upon conversion of all previously sold 2019 notes
being freely tradable pursuant to an effective registration
statement filed with the SEC or pursuant to Rule 144 under the
Securities Act.</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 1px 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
 </p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 0pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
On February 28, 2014, the Company entered into the Amendment,
which modified the terms of the Facility Agreement to provide for
the issuance of Tranche B notes to Deerfield in a maximum principal
amount equal to (i) if the FDA approves the NDA for AFREZZA
and Deerfield purchased the fourth tranche of 2019 notes, 150% of
the aggregate principal amount of the 2019 notes that Deerfield has
converted into the Company’s common stock on and after the
effective date of the Amendment, up to $90.0 million, and
(ii) otherwise, 33.33% of the aggregate principal amount of
the 2019 notes that Deerfield has converted into the
Company’s common stock on and after the effective date of the
Amendment, up to $20.0 million, in each case subject to the
satisfaction of certain other conditions. The Tranche B notes bear
interest at the rate of 9.75% per year, subject to reduction
to 8.75% if the Company enters into a collaboration with a third
party to commercialize AFREZZA, on the outstanding principal
amount, payable in cash quarterly in arrears on the last business
day of March, June, September and December of each year. The
Company is required to repay 25% of the original principal amount
of any Tranche B notes on the third, fourth, fifth and sixth
anniversaries of the applicable issue dates of such notes, provided
that the entire outstanding principal amount of all Tranche B notes
will become due and payable no later than December 31, 2019.
The Tranche B notes can be prepaid without penalty or premium
commencing two years after issuance thereof.</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
In addition, pursuant to the Amendment, the outstanding first
tranche of 2019 notes (the “Tranche 1 notes”) and third
tranche of 2019 notes (the “Tranche 3 notes”) held by
Deerfield were amended and restated such that Deerfield may,
subject to certain limitations, convert up to an additional $60.0
million principal amount under such 2019 notes into common stock
after the effective date of the Amendment, at a minimum conversion
price of $5.00 per share. The Company also agreed to register for
resale up to 12,000,000 shares of common stock issuable upon
conversion of the outstanding 2019 notes, as amended and restated,
as of the date of the Amendment.</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 18pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
<i>Commitment Asset</i></p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 6pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
In connection with the issuance of the Tranche 1 notes and the
Milestone Rights, the Company recorded a commitment asset, or the
Commitment Asset, on July 1, 2013. As a result of the
Amendment, the Company recorded an additional commitment asset with
an estimated fair value equal to $2.9 million. The Commitment Asset
remaining as of March 31, 2014 represents the right to receive
$40.0 million funding under tranche 4 of 2019 notes and up to $90
million of funding under Tranche B notes, subject to the
achievement of certain milestones, pursuant to the Facility
Agreement, as amended. The Commitment Asset is derecognized and
recorded as a debt discount on the 2019 notes and Tranche B notes
when issued and amortized using the effective interest rate method
over the life of the notes. Prior to derecognition occurring, the
Company monitors the Commitment Asset on an ongoing basis to
determine whether an impairment indicator is present that would
result in a full or partial write down of the Commitment Asset as a
result of events that may lead to the subsequent tranches of notes
not being issued. Based on the monitoring procedures performed
through March 31, 2014, the Company did not identify any
indicators of impairment.</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 18pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
<i>Amendment to the outstanding Tranche 1 and Tranche 3
notes</i></p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 6pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
The amendment and restatement of the outstanding Tranche 1 and
Tranche 3 notes, pursuant to the Amendment, did not represent a
troubled debt restructuring in the notes because the Amendment did
not result in Deerfield granting a concession to the Company. In
addition, the Amendment did not result in a substantial
modification to the terms of the Tranche 1 and Tranche 3 notes.</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
The impact of the Amendment to the Tranche 1 and Tranche 3 notes
will be accounted for as a prospective yield adjustment.
Specifically the value of the Tranche B Commitment Asset was
considered a fee received from the creditor as consideration for
the Amendment and will be amortized as an adjustment of interest
expense over the remaining term of the Tranche 1 and Tranche 3
notes using the effective interest method. As a result of the
Amendment, the value of the Tranche B Commitment Asset was
allocated between the Tranche 1 and Tranche 3 notes, which
decreased the amount of debt discount on the Tranche 1 and Tranche
3 notes.</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 18pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
<i>Conversion Option</i></p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 6pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
For accounting purposes, the Company evaluated the embedded
conversion option in the 2019 notes as a redemption feature because
the number of shares issuable upon conversion is based on the
volume weighted average prices for specified periods prior to the
conversion date (as opposed to being fixed). Accordingly,
conversions by Deerfield were treated as redemptions of the 2019
notes and, as discussed below, the Company analyzed whether the
conversion option required bifurcation as an embedded redemption
feature. As of December 31, 2013, Deerfield had converted $6.5
million principal amount of the second tranche of 2019 notes (the
“Tranche 2 notes”) for equity, resulting in an issuance
of 1,293,224 shares of the Company’s common stock. Upon
the conversion, the principal balance of the notes were recorded in
equity and an expense was recognized in the Statement of Operations
in the amount of $0.6 million for the difference between the
principal amount of the notes converted and their carrying amount
(which included unamortized discount and debt issuance costs).</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
During January 2014, Deerfield elected to convert the remaining
$33.5 million of Tranche 2 notes, which resulted in the issuance of
6,559,251 shares of the Company’s common stock. During the
three months ended March 31, 2014, the Company recorded an
expense of $3.0 million for the difference between the principal
amount of the notes converted and their carrying amount (which
included unamortized discount and debt issuance costs).</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
In March 2014, following the Amendment, which allowed Deerfield to
convert up to an additional $60 million principal amount under the
outstanding Tranche 1 and Tranche 3 notes, Deerfield elected to
convert the full $40.0 million of outstanding principal amount of
the Tranche 3 notes and $12.5 million of principal amount of the
Tranche 1 notes, pursuant to which the Company issued Deerfield
7,121,120 and 2,142,709 shares of the Company’s common stock,
respectively. As a result of these conversions, the Company
recorded the principal balance of the notes in equity and an
expense of $3.0 million for the difference between the
principal amount of the notes converted and their carrying amount
(which included the unamortized discount and debt issuance costs)
and the write-off of the derivative liability that was previously
bifurcated from the Tranche 3 notes.</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 1px 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
 </p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 0pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
In addition, the Company considered whether the amendment to the
2019 notes would result in the bifurcation of the conversion option
in the Tranche 1 notes. Upon the issuance of the Tranche 1 notes on
July 1, 2013 and as of March 31, 2014, the Company
concluded that the conversion option was not required to be
separated primarily due to the discount in the Tranche 1 notes not
being deemed substantial under ASC 815-15-25-26.</p>
<br class="Apple-interchange-newline" />
</div>
-36990000
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
The components and activity from initial recording of the facility
financing agreement recorded through March 31, 2014 consist of
the following (in thousands):</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
<tr>
<td width="87%"></td>
<td valign="bottom" width="6%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>March 31,<br />
2014</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
<b>2019 notes</b></p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Initial principal amount</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">120,000</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Principal converted to equity</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(92,500</td>
<td valign="bottom" nowrap="nowrap">) </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Debt discount-net of amortization</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(1,546</td>
<td valign="bottom" nowrap="nowrap">) </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Unaccreted debt issuance expense</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(83</td>
<td valign="bottom" nowrap="nowrap">) </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Net carrying amount of facility financing agreement</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">25,871</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
<b>Milestone Rights</b></p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Initial milestone rights fair value</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">16,276</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Debt discount-net of amortization</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(51</td>
<td valign="bottom" nowrap="nowrap">) </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Unaccreted debt issuance expense</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(61</td>
<td valign="bottom" nowrap="nowrap">) </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Less current portion of milestone rights included in other current
liabilities</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(3,151</td>
<td valign="bottom" nowrap="nowrap">) </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Net carrying amount included in other liabilities</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">13,013</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
<b>Commitment Asset</b></p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Initial commitment asset fair value</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">13,393</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Tranche B commitment asset fair value</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">2,921</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Less Tranche 2 portion of commitment asset</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(3,656</td>
<td valign="bottom" nowrap="nowrap">) </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Less Tranche 3 portion of commitment asset</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(4,580</td>
<td valign="bottom" nowrap="nowrap">) </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Commitment asset value included in other assets</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">8,078</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
</tr>
</table>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b>13. Fair Value of Financial Instruments</b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
The Company applies various valuation approaches in determining the
fair value of its financial assets and liabilities within a
hierarchy that maximizes the use of observable inputs and minimizes
the use of unobservable inputs by requiring that observable inputs
be used when available. Observable inputs are inputs that market
participants would use in pricing the asset or liability based on
market data obtained from sources independent of the Company.
Unobservable inputs are inputs that reflect the Company’s
assumptions about the inputs that market participants would use in
pricing the asset or liability and are developed based on the best
information available in the circumstances. The fair value
hierarchy is broken down into three levels based on the source of
inputs as follows:</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
Level 1— Quoted prices for identical instruments in active
markets.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
Level 2— Quoted prices for similar instruments in active
markets; quoted prices for identical or similar instruments in
markets that are not active; and model-derived valuations whose
inputs are observable or whose significant value drivers are
observable.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 75px; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
Level 3— Significant inputs to the valuation model are
unobservable.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
The availability of observable inputs can vary among the various
types of financial assets and liabilities. To the extent that the
valuation is based on models or inputs that are less observable or
unobservable in the market, the determination of fair value
requires more judgment. In certain cases, the inputs used to
measure fair value may fall into different levels of the fair value
hierarchy. In such cases, for financial statement disclosure
purposes, the level in the fair value hierarchy within which the
fair value measurement is categorized is based on the lowest level
input that is significant to the overall fair value
measurement.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<i>Cash and cash equivalents</i></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
Cash equivalents consist of highly liquid investments with original
or remaining maturities of 90 days or less at the time of purchase,
that are readily convertible into cash. As of March 31, 2014
and December 31, 2013, the Company held $35.8 million and
$70.8 million, respectively, of cash and cash equivalents,
consisting primarily of money market funds of $34.9 million and
$67.7 million, respectively, and the remaining in non-interest
bearing checking accounts. The fair value of these money market
funds was determined by using quoted prices for identical
investments in an active market (Level 1 in the fair value
hierarchy).</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
The following is a summary of the carrying values and estimated
fair values of the Company’s 5.75% Senior Convertible Notes
due 2015 (the “2015 notes”) and the 2019 notes (in
millions).</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 </p>
<table style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
<tr>
<td width="66%"></td>
<td valign="bottom" width="5%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="5%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="5%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="5%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>March 31, 2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>December 31, 2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Carrying<br />
value</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Estimated<br />
fair value</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Carrying<br />
value</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Estimated<br />
fair value</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
2015 notes</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">98.7</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">95.1</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">98.4</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">102.2</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
2019 notes</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">25.9</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">25.7</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">102.3</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">107.0</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 </p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<i>Senior Convertible Notes</i></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
The estimated fair value of the 2015 notes was calculated based on
model-derived valuations whose inputs were observable, such as the
Company’s stock price, and non-observable, such as the
Company’s longer-term historical volatility (Level 3 in the
fair value hierarchy). As there is no current observable market for
the 2015 notes, the Company determined the estimated fair value
using a convertible bond valuation model within a lattice
framework. The convertible bond valuation model combined expected
cash outflows with market-based assumptions regarding risk-adjusted
yields, stock price volatility and recent price quotes and trading
information regarding Company issued debt instruments and shares of
common stock into which the notes are convertible.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<i>Facility financing agreement</i></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
As discussed in Note 11 — Facility financing agreement, in
connection with the Facility Agreement, the Company issued 2019
notes and Milestone Rights and recorded the Commitment Asset on
July 1, 2013. As there is no current observable market for the
2019 notes, the Company determined the estimated fair value using a
bond valuation model based on a discounted cash flow methodology.
The bond valuation model combined expected cash flows associated
with principal repayment and interest based on the contractual
terms of the debt agreement discounted to present value using a
selected market discount rate of 12.7% (Level 3 in the fair value
hierarchy). On March 31, 2014, the market discount rate was
recalculated at 12.5% for the Tranche 1 notes. The Tranche 2 and
Tranche 3 notes were fully converted by the end of the first
quarter.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
The estimated fair value of the Milestone Rights was calculated
using the income approach in which the cash flows associated with
the specified contractual payments were adjusted for both the
expected timing and the probability of achieving the milestones
discounted to present value using a selected market discount rate
(Level 3 in the fair value hierarchy). The expected timing and
probability of achieving the milestones, starting in 2014, was
developed with consideration given to both internal data, such as
progress made to date and assessment of criteria required for
achievement, and external data, such as market research studies.
The discount rate (17.5%) was selected based on an estimation
of required rate of returns for similar investment opportunities
using available market data.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
The fair value of the Commitment Asset was estimated using the
income approach by estimating the fair value of the future tranches
using a market debt rate (12%) commensurate with the risk of
the future tranches and the fair value of the cash expected to be
received by the Company and assessing the probability of the
commitments being funded in the future based on the operational
hurdles required for funding being met (Level 3 in the fair value
hierarchy).</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
At March 31, 2014, as there had been no material changes to
the established estimates, the carrying value of the Milestone
Rights and Commitment Asset approximates their respective estimated
fair values.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
Also as discussed in Note 11 – Facility financing agreement,
on February 28, 2014, the Company entered into the Amendment
to Facility Agreement, and recorded an additional commitment asset
which represented the increase in borrowing capacity that the
Company received as consideration for the modifications made to the
Facility Agreement and the Tranche 1 notes and Tranche 3 notes. The
fair value of the additional commitment asset was estimated using a
discounted cash flow analysis under the income approach.
Specifically, the fair value of the additional commitment asset was
determined by estimating the fair value of the future tranche using
a market yield (11.9%) commensurate with the risk of the
future tranche and the fair value of the cash expected to be
received by the Company and assessing the probability of the
commitment being funded in the future based on the operational
hurdles required for funding being met as well as consideration of
alternative funding options (Level 3 in the fair value hierarchy).
As of February 28, 2014, the additional commitment asset was
valued at $2.9 million. At March 31, 2014, as there have been
no material changes to the established estimates, the carrying
value of the Tranche B Commitment Asset approximates its respective
estimated fair values.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
There were no material re-measurements to fair value during the
three months ended March 31, 2014 and 2013 of financial assets
and liabilities that are not measured at fair value on a recurring
basis. There were no transfers of assets or liabilities
between the fair value measurement levels during the three months
ended March 31, 2014 and 2013.</p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
Accretion of debt issuance cost and debt discount in connection
with the Facility financing agreement during the three months ended
March 31, 2014 are as follows (in thousands):</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
<tr>
<td width="78%"></td>
<td valign="bottom" width="17%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Three months ended<br />
March 31, 2014</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Accretion expense- debt issuance cost</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">282</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Accretion expense- debt discount</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">6,367</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
</table>
</div>
<div>
<p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Accrued expenses and other current liabilities are comprised of the
following (in thousands):</p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 </p>
<table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
<tr>
<td width="76%"></td>
<td valign="bottom" width="6%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="6%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="font-family:Times New Roman; font-size:8pt">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>March 31,<br />
2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>December 31,<br />
2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Salary and related expenses</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">6,650</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">12,193</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Research and clinical trial costs</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,304</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,311</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Accrued interest</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">958</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">2,082</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Construction in progress</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">370</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">342</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Other</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">5,724</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">5,706</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-size:1px;">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Accrued expenses and other current liabilities</p>
</td>
<td valign="bottom"><font style="font-size:8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">15,006</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"><font style="font-size:8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">21,634</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-size:1px;">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td> </td>
</tr>
</table>
</div>
P4Y
<div>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<b>2. Accrued expenses and other current liabilities</b></p>
<p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Accrued expenses and other current liabilities are comprised of the
following (in thousands):</p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 </p>
<table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
<tr>
<td width="76%"></td>
<td valign="bottom" width="6%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="6%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="font-family:Times New Roman; font-size:8pt">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>March 31,<br />
2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>December 31,<br />
2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Salary and related expenses</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">6,650</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">12,193</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Research and clinical trial costs</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,304</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,311</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Accrued interest</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">958</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">2,082</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Construction in progress</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">370</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">342</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Other</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">5,724</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">5,706</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-size:1px;">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Accrued expenses and other current liabilities</p>
</td>
<td valign="bottom"><font style="font-size:8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">15,006</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"><font style="font-size:8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">21,634</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-size:1px;">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td> </td>
</tr>
</table>
</div>
368784000
<div>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b>10. Senior convertible notes</b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
Senior convertible notes consist of the following (in
thousands):</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
<tr>
<td width="74%"></td>
<td valign="bottom" width="6%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="6%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>March 31,<br />
2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December 31,<br />
2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
<b>2015 notes</b></p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"> </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Principal amount</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">100,000</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"> </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">100,000</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Unaccreted debt issuance expense</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(1,338</td>
<td valign="bottom" nowrap="nowrap">) </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(1,561</td>
<td valign="bottom" nowrap="nowrap">) </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Net carrying amount</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">98,662</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt"> </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">98,439</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td> </td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
On August 18, 2010, the Company completed a Rule 144A offering
of $100.0 million aggregate principal amount of 5.75% Senior
Convertible Notes due 2015 (the “2015 notes”). The 2015
notes are governed by the terms of an indenture dated as of
August 24, 2010 (the “2015 Note Indenture”). The
2015 notes bear interest at the rate of 5.75% per year on the
principal amount, payable in cash semi-annually in arrears on
February 15 and August 15 of each year, beginning
February 15, 2011. In connection with the 2015 notes, the
Company had accrued interest of $1.0 million and $2.4 million as of
March 31, 2014 and December 31, 2013, respectively. The
2015 notes are general, unsecured, senior obligations of the
Company and effectively rank junior in right of payment to all of
the Company’s secured debt, to the extent of the value of the
assets securing such debt, and to the debt and all other
liabilities of the Company’s subsidiaries. The maturity date
of the 2015 notes is August 15, 2015 and payment is due in
full on that date for unconverted securities. Holders of the 2015
notes may convert, at any time prior to the close of business on
the business day immediately preceding the stated maturity date,
any outstanding principal into shares of the Company’s common
stock at an initial conversion rate of 147.0859 shares per $1,000
principal amount, which is equal to a conversion price of
approximately $6.80 per share, subject to adjustment. Except in
certain circumstances, if the Company undergoes a fundamental
change: (1) the Company will pay a make-whole premium on the
2015 notes converted in connection with a fundamental change by
increasing the conversion rate on such 2015 notes, which amount, if
any, will be based on the Company’s common stock price and
the effective date of the fundamental change, and (2) each
holder of 2015 notes will have the option to require the Company to
repurchase all or any portion of such holder’s 2015 notes at
a repurchase price of 100% of the principal amount of the 2015
notes to be repurchased plus accrued and unpaid interest, if any.
The Company may elect to redeem some or all of the 2015 notes if
the closing stock price has equaled 150% of the conversion price
for at least 20 of the 30 consecutive trading days ending on the
trading day before the Company’s redemption notice. The
redemption price will equal 100% of the principal amount of the
2015 notes to be redeemed, plus accrued and unpaid interest, if
any, to, but excluding, the redemption date, plus a make-whole
payment equal to the sum of the present values of the remaining
scheduled interest payments through and including August 15,
2015 (other than interest accrued up to, but excluding, the
redemption date). The Company will be obligated to make the
make-whole payment on all the 2015 notes called for redemption and
converted during the period from the date the Company mailed the
notice of redemption to and including the redemption date. The
Company may elect to make the make-whole payment in cash or shares
of its common stock, subject to certain limitations. Under the
terms of the 2015 Note Indenture, the conversion option can be
net-share settled and the maximum number of shares that could be
required to be delivered under the contract, including the
make-whole shares, is fixed and less than the number of authorized
and unissued shares less the maximum number of shares that could be
required to be delivered during the contract period under existing
commitments. Applying the Company’s sequencing policy, the
Company performed an analysis at the time of the offering of the
2015 notes and each reporting date since and has concluded that the
number of available authorized shares at the time of the offering
and each subsequent reporting date was sufficient to deliver the
number of shares that could be required to be delivered during the
contract period under existing commitments.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
The Company incurred approximately $4.2 million in issuance costs
which are recorded as an offset to the 2015 notes in the
accompanying condensed consolidated balance sheets. These costs are
being accreted to interest expense using the effective interest
method over the term of the 2015 notes.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
The 2015 notes provide that upon an acceleration of certain
indebtedness, which would include the 2019 notes or the Tranche B
notes described in Note 11, the holders may elect to accelerate the
Company’s repayment obligations under the notes if such
acceleration is not cured, waived, rescinded or annulled. There can
be no assurance that the holders would not choose to exercise these
rights in the event such events were to occur.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
Accretion of debt issuance expense in connection with the 2015
notes during the three months ended March 31, 2014 and 2013
was $223,000 and $209,000, respectively.</p>
</div>
46400
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
Total stock-based compensation expense recognized in the
accompanying condensed consolidated statements of operations for
the three months ended March 31, 2014 and 2013 was as follows
(in thousands):</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
<tr>
<td width="81%"></td>
<td valign="bottom" width="4%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="4%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three months ended<br />
March 31,</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Stock-based compensation</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">10,937</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">5,189</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
</tr>
</table>
</div>
<div>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<b>4. Net loss per common share</b></p>
<p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Basic net loss per share excludes dilution for potentially dilutive
securities and is computed by dividing net loss applicable to
common stockholders by the weighted average number of common shares
outstanding during the period excluding the shares loaned to Bank
of America, N.A. under a share lending arrangement (see Note 7
— Common and preferred stock). As of March 31, 2014,
9,000,000 shares of the Company’s common stock, which were
loaned to Bank of America, N.A. pursuant to the terms of a share
lending agreement as described in Note 7, were issued and are
outstanding, and holders of the borrowed shares have all the rights
of a holder of the Company’s common stock. However, because
the share borrower must return all borrowed shares to the Company
(or, in certain circumstances, the cash value thereof), the
borrowed shares are not considered outstanding for the purpose of
computing and reporting basic or diluted earnings (loss) per share.
Diluted net loss per share reflects the potential dilution that
could occur if securities or other contracts to issue common stock
were exercised or converted into common stock. Potentially dilutive
securities are excluded from the computation of diluted net loss
per share for all of the periods presented in the accompanying
condensed consolidated statements of operations because the
reported net loss in each of these periods results in their
inclusion being antidilutive. Antidilutive securities, which
consist of stock options, restricted stock units, warrants, and
shares that could be issued upon conversion of the senior
convertible notes and conversion of the facility financing
obligation, that are not included in the diluted net loss per share
calculation consisted of an aggregate of 67,791,150 shares and
133,500,568 shares as of March 31, 2014 and 2013,
respectively, and exclude the 9,000,000 shares loaned under the
share lending arrangement.</p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>9. Related-party arrangements</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
In October 2007, the Company entered into a $350.0 million loan
arrangement with its principal stockholder. The Loan Arrangement
has been amended from time to time. On October 31, 2013, the
promissory note underlying the Loan Arrangement was amended to,
among other things, extend the maturity date of the loan to
January 5, 2020, extend the date through which the Company can
borrow under the Loan Arrangement to December 31, 2019,
increase the aggregate borrowing amount under the Loan Arrangement
from $350.0 million to $370.0 million and provide that repayments
or cancellations of principal under the Loan Arrangement will not
be available for reborrowing.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
As of March 31, 2014, the total principal amount outstanding
under the Loan Arrangement was $49.5 million, and the amount
available for future borrowings was $30.1 million. Interest, at a
fixed rate of 5.84%, is due and payable quarterly in arrears
on the first day of each calendar quarter for the preceding
quarter, or at such other time as the Company and The Mann Group
mutually agree. All or any portion of accrued and unpaid interest
that becomes due and payable may be paid-in-kind and capitalized as
additional borrowings at any time and would be classified as
non-current upon mutual agreement of both parties. As of
March 31, 2014, the Company had accrued $1.3 million of
interest in other liabilities related to the Loan Arrangement. The
Mann Group can require the Company to prepay up to $200.0 million
in advances that have been outstanding for at least 12 months (less
approximately $105.0 million aggregate principal amount that has
been cancelled in connection with two common stock purchase
agreements). If The Mann Group exercises this right, the Company
will have 90 days after The Mann Group provides written notice (or
the number of days to maturity of the note if less than
90 days) to prepay such advances. However, pursuant to a
letter agreement entered into in August 2010, The Mann Group has
agreed to not require the Company to prepay amounts outstanding
under the amended and restated promissory note if the prepayment
would require the Company to use its working capital resources. In
addition, The Mann Group entered into a subordination agreement
with Deerfield pursuant to which The Mann Group agreed with
Deerfield not to demand or accept any payment under the Loan
Arrangement until the Company’s payment obligations to
Deerfield under the Facility Agreement have been satisfied in full.
Subject to the foregoing, in the event of a default under the Loan
Arrangement, all unpaid principal and interest either becomes
immediately due and payable or may be accelerated at The Mann
Group’s option, and the interest rate will increase to the
one-year LIBOR calculated on the date of the initial advance or in
effect on the date of default, whichever is greater, plus
5% per annum. All borrowings under the Loan Arrangement are
unsecured. The Loan Arrangement contains no financial
covenants.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
During the first quarter of 2014, there were no borrowings under or
amendments to the Loan Arrangement.</p>
</div>
17700
67791150
<div>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
<b>1. Description of business and basis of presentation</b></p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 6pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
The accompanying unaudited condensed consolidated financial
statements of MannKind Corporation and its subsidiaries (
“MannKind” or the “Company”), have been
prepared in accordance with generally accepted accounting
principles in the United States of America (“GAAP”) for
interim financial information and with the instructions to Form
10-Q and Article 10 of Regulation S-X of the Securities and
Exchange Commission (the “SEC”). Accordingly, they do
not include all of the information and footnotes required by GAAP
for complete financial statements. The information included in this
quarterly report on Form 10-Q should be read in conjunction with
the audited consolidated financial statements and notes thereto
included in the Company’s annual report on Form 10-K for the
fiscal year ended December 31, 2013 filed with the SEC on
March 3, 2014 (the “Annual Report”).</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
In the opinion of management, all adjustments, consisting only of
normal, recurring adjustments, considered necessary for a fair
presentation of the results of these interim periods have been
included. The results of operations for the three months ended
March 31, 2014 may not be indicative of the results that may
be expected for the full year.</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
The preparation of financial statements in conformity with GAAP
requires management to make estimates and assumptions that affect
the amounts reported in the financial statements and accompanying
notes. Actual results could differ from those estimates or
assumptions. The more significant estimates reflected in these
accompanying financial statements involve assessing long-lived
assets for impairment, accrued expenses, including clinical study
expenses, valuation of forward purchase contracts, valuation of the
facility financing obligation, commitment asset, milestone rights,
valuation of stock-based compensation and the determination of the
provision for income taxes and corresponding deferred tax assets
and liabilities and any valuation allowance recorded against net
deferred tax assets. The estimation process often may yield a range
of potentially reasonable estimates of the ultimate future outcomes
and management must select an amount that falls within that range
of reasonable estimates. This process may result in actual results
differing materially from those estimated amounts used in the
preparation of the financial statements.</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
<b><i>Business — </i></b>The Company is a
biopharmaceutical company focused on the discovery and development
of therapeutic products for diseases such as diabetes. The
Company’s lead product candidate, AFREZZA (insulin human
[rDNA origin]) inhalation powder, is an ultra rapid-acting insulin
therapy that is in late-stage clinical investigation for the
treatment of adults with type 1 or type 2 diabetes for the control
of hyperglycemia.</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
Last October, the Company resubmitted a New Drug Application
(“NDA”) for AFREZZA to the U.S. Food and Drug
Administration (“FDA”), which included data from two
completed Phase 3 studies 171 and 175, both of which met their
primary efficacy endpoints and safety objectives. On
April 1, 2014 the Endocrinologic and Metabolic Drugs Advisory
Committee (“EMDA”) of the FDA voted 13 to 1 to
recommend that AFREZZA inhalation powder be granted approval by the
FDA to improve glycemic control in adults with type 1 diabetes and
voted 14 to 0 to recommend that AFREZZA be granted approval by the
FDA to improve glycemic control in adults with type 2 diabetes.</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
Subsequent to the EMDA meeting, the FDA extended the Prescription
Drug User Fee Act (“PDUFA”) date for AFREZZA by
three months from April 15, 2014 to July 15, 2014 in
order to provide time for a full review of information submitted
by the Company in response to the FDA’s
requests.</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
<b><i>Basis of Presentation — </i></b>The Company is
considered to be in the development stage as its primary activities
since incorporation have been establishing its facilities,
recruiting personnel, conducting research and development, business
development, business and financial planning, and raising capital.
It is costly to develop therapeutic products and conduct clinical
studies for these products. From its inception through
March 31, 2014, the Company has reported accumulated net
losses of $2.3 billion, which include a goodwill impairment charge
of $151.4 million and cumulative negative cash flow from operations
of $1.8 billion. At March 31, 2014, the Company’s
capital resources consisted of cash and cash equivalents of $35.8
million. These factors raise substantial doubt about the
Company’s ability to continue as a going concern. The
financial statements do not include any adjustments that might
result from the outcome of these uncertainties.</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
As of March 31, 2014, the Company had $30.1 million principal
amount of available borrowings under its loan arrangement (the
“Loan Arrangement”) with The Mann Group LLC (“The
Mann Group”) although the Company anticipates using a portion
of these available borrowings to capitalize accrued interest into
principal as it becomes due and payable under the Loan Arrangement,
upon mutual agreement of the parties. As of March 31, 2014,
the Company had accrued $1.3 million of interest related to the
Loan Arrangement.</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
On July 1, 2013, the Company entered into a facility agreement
(the “Facility Agreement”) with Deerfield Private
Design Fund II, L.P. (“Deerfield Private Design Fund”)
and Deerfield Private Design International II, L.P. (collectively,
“Deerfield”), providing for the sale of up to $160.0
million of Senior Convertible Notes due 2019 (the “2019
notes”) to Deerfield in four equal tranches of $40.0 million
principal amount. As of March 31, 2014, Deerfield had
purchased the first three tranches of 2019 notes in the aggregate
principal amount of $120.0 million; therefore, only $40.0 million
remain unsold. Deerfield’s obligation to purchase the fourth
tranche of 2019 notes is subject to the receipt of marketing
approval of AFREZZA by the FDA and the shares of common stock
issuable upon conversion of all previously sold 2019 notes being
freely tradable pursuant to an effective registration statement
filed with the SEC or pursuant to Rule 144 under the Securities
Act. On February 28, 2014, the Company entered into a First
Amendment to Facility Agreement and Registration Rights Agreement
(the “Amendment”). The Amendment modified the terms of
the Facility Agreement that was entered into on July 1, 2013
with Deerfield to provide for the issuance of an additional tranche
of notes (the “Tranche B notes”) to Deerfield in a
maximum principal amount equal to (x) if the FDA approves the
NDA for AFREZZA and Deerfield purchased the fourth tranche of 2019
notes, 150% of the aggregate principal amount of the 2019 notes
that Deerfield has converted into the Company’s common stock
on and after the effective date of the Amendment, up to $90.0
million, and (y) otherwise, 33.33% of the aggregate principal
amount of the 2019 notes that Deerfield has converted into the
Company’s common stock on and after the effective date of the
Amendment, up to $20.0 million, in each case subject to the
satisfaction of certain other conditions. The Facility Agreement
contains a financial covenant that requires the Company’s
cash and cash equivalents, which include available borrowings under
the Loan Arrangement, on the last day of each fiscal quarter to not
be less than $25 million. Based on its current expectations, the
Company believes that its existing capital resources will enable it
to continue planned operations at least into the third quarter of
2014. However, the Company cannot provide assurances that its plans
will not change or that changed circumstances will not result in
the depletion of its capital resources more rapidly than it
currently anticipates. The Company will need to raise additional
capital, whether through the sale of equity or debt securities, a
strategic business collaboration with a pharmaceutical company, the
establishment of other funding facilities, licensing arrangements,
asset sales or other means, in order to continue the development of
and to commercialize AFREZZA and other product candidates and to
support its other ongoing activities. However, the Company cannot
provide assurances that such additional capital will be available
on favorable terms, or at all.</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
Capital resources potentially available to the Company include
proceeds from the exercise of warrants issued in its February 2012
public offering, the Company’s at-the-market issuance sales
agreements, and issuance of additional 2019 notes and/or
Tranche B notes to Deerfield (see Note 11 – Facility
financing agreement).</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
<b><i>Fair Value of Financial Instruments — </i></b>The carrying amounts
reported in the accompanying financial statements for cash and cash
equivalents, accounts payable and accrued liabilities approximate
their fair value due to their relatively short maturities. The fair
value of the cash equivalents, note payable to related party,
senior convertible notes, and the Facility Agreement are discussed
in Note 13, “Fair Value Measurements.”</p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12pt; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: 10pt 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0pt; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
<b><i>Recently Issued Accounting Standards
—</i></b> In
July 2013, the FASB issued ASU 2013-11,<i> Income Taxes (Topic
740): Presentation of an Unrecognized Tax Benefit when a Net
Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit
Carryforward Exists (a consensus of the FASB Emerging Issues Task
Force)</i>. The amendments in this ASU provide guidance on the
financial statements presentation of an unrecognized tax benefit
when a net operating loss carryforward, a similar tax loss, or a
tax credit carryforward exists. An unrecognized tax benefit should
be presented in the financial statements as a reduction to a
deferred tax asset for a net operating loss carryforward, a similar
tax loss, or a tax credit carryforward with certain exceptions, in
which case such an unrecognized tax benefit should be presented in
the financial statements as a liability. The amendments in this ASU
do not require new recurring disclosures. The amendments in this
ASU are effective for fiscal years, and interim periods within
those years, beginning after December 15, 2013. The adoption
of the new requirement did not have a significant impact on the
Company’s consolidated financial statements.</p>
</div>
<font size="2"><strong><em>Fair Value of Financial Instruments
— </em></strong>The
carrying amounts reported in the accompanying financial statements
for cash and cash equivalents, accounts payable and accrued
liabilities approximate their fair value due to their relatively
short maturities. The fair value of the cash equivalents, note
payable to related party, senior convertible notes, and the
Facility Agreement are discussed in Note 13, “Fair Value
Measurements.”</font>
-0.14
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>14. Subsequent Events</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
On April 1, 2014 the EMDA voted 13 to 1 to recommend that
AFREZZA inhalation powder be granted approval by the FDA to improve
glycemic control in adults with type 1 diabetes and voted 14 to 0
to recommend that AFREZZA be granted approval by the FDA to improve
glycemic control in adults with type 2 diabetes.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
Subsequent to the EMDA meeting, the FDA extended the PDUFA date for
AFREZZA by three months from April 15, 2014 to July
15, 2014 in order to provide time for a full review of
information submitted by MannKind in response to
the FDA’s requests.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
On April 2, 2014, Deerfield elected to convert an aggregate of
$7.5 million of principal amount of the Tranche 1 notes, pursuant
to which the Company issued Deerfield 1,500,000 shares of the
Company’s common stock. As a result of this election,
Deerfield has fully exercised the conversion option under the
Amendment by converting the additional $60.0 million of the Tranche
1 and Tranche 3 notes allowable, into 10,763,829 shares of the
Company’s common stock in the aggregate.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
On May 6, 2014, Deerfield purchased an aggregate principal
amount of $20.0 million in Tranche B notes in accordance with the
provisions of the Facility Agreement, as amended.</p>
</div>
P1Y10M6D
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>12. Income taxes</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
As required by ASC 740 <i>Income Taxes</i> (“ASC 740”),
management of the Company has evaluated the positive and negative
evidence bearing upon the realizability of its deferred tax assets
and concluded, in accordance with the applicable accounting
standards, that net deferred tax assets should be fully
reserved.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
ASC 740-10-25 <i>Income Taxes Recognition</i> clarifies the
accounting and disclosure for uncertainty in tax positions, as
defined. This guidance seeks to reduce the diversity in practice
associated with certain aspects of the recognition and measurement
related to accounting for income taxes. The Company believes that
its income tax filing positions and deductions will be sustained on
audit and does not anticipate any adjustments that will result in a
material change to its financial position. Therefore, no reserves
for uncertain income tax positions have been recorded pursuant to
this guidance. Tax years since 1993 remain subject to examination
by the major tax jurisdictions in which the Company is subject to
tax.</p>
</div>
<div>
<p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Senior convertible notes consist of the following (in
thousands):</p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 </p>
<table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
<tr>
<td width="74%"></td>
<td valign="bottom" width="6%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="6%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="font-family:Times New Roman; font-size:8pt">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>March 31,<br />
2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>December 31,<br />
2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
<b>2015 notes</b></p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"> </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
<tr style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Principal amount</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">100,000</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">100,000</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Unaccreted debt issuance expense</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(1,338</td>
<td nowrap="nowrap" valign="bottom">) </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">(1,561</td>
<td nowrap="nowrap" valign="bottom">) </td>
</tr>
<tr style="font-size:1px;">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1.00px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Net carrying amount</p>
</td>
<td valign="bottom"><font style="font-size:8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">98,662</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom"><font style="font-size:8pt"> </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">98,439</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-size:1px;">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td> </td>
</tr>
</table>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>3. Accounting for stock-based compensation</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
Total stock-based compensation expense recognized in the
accompanying condensed consolidated statements of operations for
the three months ended March 31, 2014 and 2013 was as follows
(in thousands):</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
<tr>
<td width="81%"></td>
<td valign="bottom" width="4%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="4%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three months ended<br />
March 31,</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Stock-based compensation</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">10,937</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">5,189</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
The Company issued stock awards to employees during the three
months ended March 31, 2014 with a four-year vesting schedule.
The grant date fair value of the 46,400 restricted stock units and
17,700 stock options issued was $296,000 and $81,000, respectively,
with a grant date fair value per share of $6.39 and $4.58,
respectively.</p>
<p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 </p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
As of March 31, 2014, there was $9.9 million and $14.0 million
of unrecognized compensation cost related to options and restricted
stock units, respectively, which are expected to be recognized over
the remaining weighted average vesting period of 1.85 years. The
Company evaluates stock awards with performance conditions as to
the probability that the performance conditions will be met and
estimates the date at which the performance conditions will be met
in order to properly recognize stock-based compensation expense
over the requisite service period. As of March 31, 2014, there
were $107,000 and $3.7 million of unrecognized expenses related to
performance options and restricted stock units, respectively, for
milestones not considered probable of achievement.</p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>8. Commitments and contingencies</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
<b><i>Guarantees and Indemnifications —</i></b> In the
ordinary course of its business, the Company makes certain
indemnities, commitments and guarantees under which it may be
required to make payments in relation to certain transactions. The
Company, as permitted under Delaware law and in accordance with its
Bylaws, indemnifies its officers and directors for certain events
or occurrences, subject to certain limits, while the officer or
director is or was serving at the Company’s request in such
capacity. The term of the indemnification period is for the
officer’s or director’s lifetime. The maximum amount of
potential future indemnification is unlimited; however, the Company
has a director and officer insurance policy that may enable it to
recover a portion of any future amounts paid. The Company believes
the fair value of these indemnification agreements is minimal. The
Company has not recorded any liability for these indemnities in the
accompanying condensed consolidated balance sheets. However, the
Company accrues for losses for any known contingent liability,
including those that may arise from indemnification provisions,
when future payment is probable and the amount can be reasonably
estimated.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
<b><i>Litigation —</i></b> The Company is subject to legal
proceedings and claims which arise in the ordinary course of its
business. As of the date hereof, the Company believes that the
final disposition of such matters will not have a material adverse
effect on the financial position, results of operations or cash
flows of the Company. The Company maintains liability insurance
coverage to protect the Company’s assets from losses arising
out of or involving activities associated with ongoing and normal
business operations. In accordance with ASC 450
<i>Contingencies</i>, the Company would record a provision for a
liability when it is both probable that a liability has been
incurred and the amount of the loss can be reasonably
estimated.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
<b><i>Contingencies —</i></b> In connection with the Facility
Agreement, on July 1, 2013 the Company also entered into a
Milestone Rights Purchase Agreement (the “Milestone
Agreement”) with Deerfield Private Design Fund and Horizon
Santé FLML SÁRL (collectively, the “Milestone
Purchasers”), pursuant to which the Company sold the
Milestone Purchasers certain rights (the “Milestone
Rights”) to receive payments of up to $90.0 million upon the
occurrence of specified strategic and sales milestones, including
the first commercial sale of an AFREZZA product and the achievement
of specified net sales figures (see Note 11 – Facility
financing agreement).</p>
</div>
1409000
86000000
1000
-52056000
1700000
-5890000
4678000
33000
-52056000
-1845000
-52056000
-41411000
0
-52056000
3368000
15229000
223000
10937000
9394000
-35031000
-1409000
4042000
41411000
1938000
-1038000
26182000
714000
2522000
10937000
0
714000
-6704000
0.01
<div>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b><i>Basis of Presentation — </i></b>The Company is
considered to be in the development stage as its primary activities
since incorporation have been establishing its facilities,
recruiting personnel, conducting research and development, business
development, business and financial planning, and raising capital.
It is costly to develop therapeutic products and conduct clinical
studies for these products. From its inception through
March 31, 2014, the Company has reported accumulated net
losses of $2.3 billion, which include a goodwill impairment charge
of $151.4 million and cumulative negative cash flow from operations
of $1.8 billion. At March 31, 2014, the Company’s
capital resources consisted of cash and cash equivalents of $35.8
million. These factors raise substantial doubt about the
Company’s ability to continue as a going concern. The
financial statements do not include any adjustments that might
result from the outcome of these uncertainties.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
As of March 31, 2014, the Company had $30.1 million principal
amount of available borrowings under its loan arrangement (the
“Loan Arrangement”) with The Mann Group LLC (“The
Mann Group”) although the Company anticipates using a portion
of these available borrowings to capitalize accrued interest into
principal as it becomes due and payable under the Loan Arrangement,
upon mutual agreement of the parties. As of March 31, 2014,
the Company had accrued $1.3 million of interest related to the
Loan Arrangement.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
On July 1, 2013, the Company entered into a facility agreement
(the “Facility Agreement”) with Deerfield Private
Design Fund II, L.P. (“Deerfield Private Design Fund”)
and Deerfield Private Design International II, L.P. (collectively,
“Deerfield”), providing for the sale of up to $160.0
million of Senior Convertible Notes due 2019 (the “2019
notes”) to Deerfield in four equal tranches of $40.0 million
principal amount. As of March 31, 2014, Deerfield had
purchased the first three tranches of 2019 notes in the aggregate
principal amount of $120.0 million; therefore, only $40.0 million
remain unsold. Deerfield’s obligation to purchase the fourth
tranche of 2019 notes is subject to the receipt of marketing
approval of AFREZZA by the FDA and the shares of common stock
issuable upon conversion of all previously sold 2019 notes being
freely tradable pursuant to an effective registration statement
filed with the SEC or pursuant to Rule 144 under the Securities
Act. On February 28, 2014, the Company entered into a First
Amendment to Facility Agreement and Registration Rights Agreement
(the “Amendment”). The Amendment modified the terms of
the Facility Agreement that was entered into on July 1, 2013
with Deerfield to provide for the issuance of an additional tranche
of notes (the “Tranche B notes”) to Deerfield in a
maximum principal amount equal to (x) if the FDA approves the
NDA for AFFREZZA and Deerfield purchased the fourth tranche of 2019
notes, 150% of the aggregate principal amount of the 2019 notes
that Deerfield has converted into the Company’s common stock
on and after the effective date of the Amendment, up to $90.0
million, and (y) otherwise, 33.33% of the aggregate principal
amount of the 2019 notes that Deerfield has converted into the
Company’s common stock on and after the effective date of the
Amendment, up to $20.0 million, in each case subject to the
satisfaction of certain other conditions. The Facility Agreement
contains a financial covenant that requires the Company’s
cash and cash equivalents, which include available borrowings under
the Loan Arrangement, on the last day of each fiscal quarter to not
be less than $25 million. Based on its current expectations, the
Company believes that its existing capital resources will enable it
to continue planned operations at least into the third quarter of
2014. However, the Company cannot provide assurances that its plans
will not change or that changed circumstances will not result in
the depletion of its capital resources more rapidly than it
currently anticipates. The Company will need to raise additional
capital, whether through the sale of equity or debt securities, a
strategic business collaboration with a pharmaceutical company, the
establishment of other funding facilities, licensing arrangements,
asset sales or other means, in order to continue the development of
and to commercialize AFREZZA and other product candidates and to
support its other ongoing activities. However, the Company cannot
provide assurances that such additional capital will be available
on favorable terms, or at all.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
Capital resources potentially available to the Company include
proceeds from the exercise of warrants issued in its February 2012
public offering, the Company’s at-the-market issuance sales
agreements, and issuance of additional 2019 notes and/or
Tranche B notes to Deerfield (see Note 11 – Facility
financing agreement).</p>
</div>
P4Y
<div>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b>7. Common and preferred stock</b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
The Company is authorized to issue 550,000,000 shares of common
stock, par value $0.01 per share, and 10,000,000 shares of
undesignated preferred stock, par value $0.01 per share, issuable
in one or more series designated by the Company’s board of
directors. No other class of capital stock is authorized. As of
March 31, 2014 and December 31, 2013, 386,934,914 and
369,391,972 shares of common stock, respectively, were issued and
outstanding and no shares of preferred stock were outstanding.
Included in the common stock outstanding as of March 31, 2014
and December 31, 2013 are 9,000,000 shares of common stock
loaned to Bank of America under a share lending agreement in
connection with the offering of $100.0 million aggregate principal
amount of 2015 notes (see Note 10 — Senior convertible
notes). Bank of America is obligated to return the borrowed shares
(or, in certain circumstances, the cash value thereof) to the
Company on or about the 45th business day following the date as of
which the entire principal amount of the 2015 notes ceases to be
outstanding, subject to extension or acceleration in certain
circumstances or early termination at Bank of America’s
option. The Company did not receive any proceeds from the sale of
the borrowed shares by Bank of America, but the Company did receive
a nominal lending fee of $0.01 per share from Bank of America for
the use of borrowed shares.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
On July 1, 2013, the Company entered into the Facility
Agreement with Deerfield providing for the sale of up to $160.0
million of 2019 notes to Deerfield in four equal tranches of $40.0
million principal amount. A portion of the principal amount of the
2019 notes were convertible into shares of the Company’s
common stock at the note holder’s option.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
On February 28, 2014, the Company amended the Facility
Agreement to, among other things, allow Deerfield, subject to
certain limitations, to convert up to an additional $60.0 million
principal amount under the then-outstanding 2019 notes into common
stock after the effective date of the Amendment, at a minimum
conversion price of $5.00 per share unless the Company otherwise
consents. The Company also agreed to register for resale up to
12,000,000 shares of common stock issuable upon conversion of the
outstanding 2019 notes, with a minimum conversion price of $5.00
per share unless the Company otherwise consents. The conversion
price will be determined by the average of the volume weighted
average prices per share during the three trading days immediately
preceding the election to convert. As of March 31, 2014,
Deerfield had converted a portion of the outstanding 2019 notes
into common stock (see Note 11 – Facility financing
agreement).</p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
<b><i>Recently Issued Accounting Standards —</i></b> In July
2013, the FASB issued ASU 2013-11,<i> Income Taxes (Topic
740): Presentation of an Unrecognized Tax Benefit when a Net
Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit
Carryforward Exists (a consensus of the FASB Emerging Issues Task
Force)</i>. The amendments in this ASU provide guidance on the
financial statements presentation of an unrecognized tax benefit
when a net operating loss carryforward, a similar tax loss, or a
tax credit carryforward exists. An unrecognized tax benefit should
be presented in the financial statements as a reduction to a
deferred tax asset for a net operating loss carryforward, a similar
tax loss, or a tax credit carryforward with certain exceptions, in
which case such an unrecognized tax benefit should be presented in
the financial statements as a liability. The amendments in this ASU
do not require new recurring disclosures. The amendments in this
ASU are effective for fiscal years, and interim periods within
those years, beginning after December 15, 2013. The adoption
of the new requirement did not have a significant impact on the
Company’s consolidated financial statements.</p>
</div>
0.65
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
<b><i>Business —</i></b> The Company is a biopharmaceutical
company focused on the discovery and development of therapeutic
products for diseases such as diabetes. The Company’s lead
product candidate, AFREZZA (insulin human [rDNA origin]) inhalation
powder, is an ultra rapid-acting insulin therapy that is in
late-stage clinical investigation for the treatment of adults with
type 1 or type 2 diabetes for the control of hyperglycemia.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
Last October, the Company resubmitted a New Drug Application
(“NDA”) for AFREZZA to the U.S. Food and Drug
Administration (“FDA”), which included data from two
completed Phase 3 studies 171 and 175, both of which met their
primary efficacy endpoints and safety objectives. On
April 1, 2014 the Endocrinologic and Metabolic Drugs Advisory
Committee (“EMDA”) of the FDA voted 13 to 1 to
recommend that AFREZZA inhalation powder be granted approval by the
FDA to improve glycemic control in adults with type 1 diabetes and
voted 14 to 0 to recommend that AFREZZA be granted approval by the
FDA to improve glycemic control in adults with type 2 diabetes.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
Subsequent to the EMDA meeting, the FDA extended the Prescription
Drug User Fee Act (“PDUFA”) date for AFREZZA by
three months from April 15, 2014 to July 15, 2014 in
order to provide time for a full review of information submitted
by the Company in response to the FDA’s
requests.</p>
</div>
-82000
<div>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<b>5. State research and development credit exchange
receivable</b></p>
<p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The State of Connecticut provides certain companies with the
opportunity to exchange certain research and development income tax
credit carryforwards for cash in exchange for forgoing the
carryforward of the research and development income tax credits.
The program provides for an exchange of research and development
income tax credits for cash equal to 65% of the value of
corporation tax credit available for exchange. There were no
current estimated amounts receivable under the program at
March 31, 2014 and December 31, 2013, respectively.
Long-term estimated amounts receivable under the program were
$380,000 and $298,000 at March 31, 2014 and December 31,
2013, respectively.</p>
</div>
<div>
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Depreciation and amortization expense related to property and
equipment for the three months ended March 31, 2014 and 2013
was as follows (in thousands):</p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 </p>
<table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" align="center">
<tr>
<td width="82%"></td>
<td valign="bottom" width="4%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="4%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="font-family:Times New Roman; font-size:8pt">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">
<b>Three months ended<br />
March 31,</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="font-family:Times New Roman; font-size:8pt">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
Depreciation and amortization expense</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">2,522</td>
<td nowrap="nowrap" valign="bottom">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">2,990</td>
<td nowrap="nowrap" valign="bottom">  </td>
</tr>
<tr style="font-size:1px;">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3.00px double #000000"> </p>
</td>
<td> </td>
</tr>
</table>
</div>
1463000
2921000
6367000
282000
2142709
12500000
1293224
3000000
600000
6500000
7121120
3000000
40000000
60000000
0.05
P12M
P5Y
P3Y
P39Y
P5Y
200000000
P40Y
P15Y
P40Y
P10Y
105000000
P90D
The interest rate will increase to the one-year LIBOR calculated on the date of the initial advance or in effect on the date of default, whichever is greater, plus 5% per annum.
0.12
4.58
81000
6.39
296000
0.175
P4Y
P3Y
0000899460
mnkd:ComputerEquipmentAndSoftwareMember
2014-01-01
2014-03-31
0000899460
us-gaap:LeaseholdImprovementsMember
2014-01-01
2014-03-31
0000899460
mnkd:MilestoneRightsLiabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:IncomeApproachValuationTechniqueMember
2014-01-01
2014-03-31
0000899460
us-gaap:RestrictedStockUnitsRSUMember
2014-01-01
2014-03-31
0000899460
us-gaap:EmployeeStockOptionMember
2014-01-01
2014-03-31
0000899460
mnkd:CommitmentAssetMemberus-gaap:FairValueInputsLevel3Memberus-gaap:IncomeApproachValuationTechniqueMember
2014-01-01
2014-03-31
0000899460
mnkd:LetterAgreementMembermnkd:RelatedPartyDebtMember
2014-01-01
2014-03-31
0000899460
mnkd:LoanArrangementMemberus-gaap:PrincipalOwnerMember
2014-01-01
2014-03-31
0000899460
mnkd:FurnitureFixturesAndOfficeEquipmentMemberus-gaap:MaximumMember
2014-01-01
2014-03-31
0000899460
us-gaap:BuildingMemberus-gaap:MaximumMember
2014-01-01
2014-03-31
0000899460
us-gaap:MachineryAndEquipmentMemberus-gaap:MaximumMember
2014-01-01
2014-03-31
0000899460
us-gaap:BuildingImprovementsMemberus-gaap:MaximumMember
2014-01-01
2014-03-31
0000899460
us-gaap:MaximumMembermnkd:LoanArrangementMemberus-gaap:PrincipalOwnerMember
2014-01-01
2014-03-31
0000899460
mnkd:FurnitureFixturesAndOfficeEquipmentMemberus-gaap:MinimumMember
2014-01-01
2014-03-31
0000899460
us-gaap:BuildingMemberus-gaap:MinimumMember
2014-01-01
2014-03-31
0000899460
us-gaap:MachineryAndEquipmentMemberus-gaap:MinimumMember
2014-01-01
2014-03-31
0000899460
us-gaap:BuildingImprovementsMemberus-gaap:MinimumMember
2014-01-01
2014-03-31
0000899460
us-gaap:MinimumMembermnkd:LoanArrangementMemberus-gaap:PrincipalOwnerMember
2014-01-01
2014-03-31
0000899460
mnkd:LetterAgreementMembermnkd:RelatedPartyDebtMemberus-gaap:LondonInterbankOfferedRateLIBORMember
2014-01-01
2014-03-31
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:TrancheOneAndTrancheThreeMembermnkd:TwoThousandNineteenNotesMemberus-gaap:MinimumMember
2014-01-01
2014-03-31
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:TrancheThreeMembermnkd:TwoThousandNineteenNotesMember
2014-01-01
2014-03-31
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:TrancheTwoMembermnkd:TwoThousandNineteenNotesMember
2014-01-01
2014-03-31
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:TrancheOneMembermnkd:TwoThousandNineteenNotesMember
2014-01-01
2014-03-31
0000899460
mnkd:DeerfieldManagementCompanyLpMember
2014-01-01
2014-03-31
0000899460
2014-01-01
2014-03-31
0000899460
2013-01-01
2013-03-31
0000899460
us-gaap:SeriesCPreferredStockMember
1991-02-14
2014-03-31
0000899460
us-gaap:SeriesBPreferredStockMember
1991-02-14
2014-03-31
0000899460
1991-02-14
2014-03-31
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:TrancheTwoMembermnkd:TwoThousandNineteenNotesMember
2014-01-01
2014-01-31
0000899460
mnkd:AmendedAgreementMemberus-gaap:PrincipalOwnerMember
2013-10-01
2013-10-31
0000899460
us-gaap:PrincipalOwnerMember
2013-10-01
2013-10-31
0000899460
us-gaap:PrincipalOwnerMember
2007-10-01
2007-10-31
0000899460
us-gaap:FairValueInputsLevel3Membermnkd:TwoThousandNineteenNotesMemberus-gaap:IncomeApproachValuationTechniqueMember
2013-06-29
2013-07-01
0000899460
mnkd:TrancheOneMemberus-gaap:FairValueInputsLevel3Membermnkd:TwoThousandNineteenNotesMemberus-gaap:IncomeApproachValuationTechniqueMember
2013-06-29
2013-07-01
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:NotesIssuedInFourEqualTranchesMembermnkd:TwoThousandNineteenNotesMember
2013-06-29
2013-06-30
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:TrancheOneAndTrancheThreeMembermnkd:TwoThousandNineteenNotesMemberus-gaap:SubsequentEventMember
2014-04-01
2014-04-02
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:TrancheOneMembermnkd:TwoThousandNineteenNotesMemberus-gaap:SubsequentEventMember
2014-04-01
2014-04-02
0000899460
mnkd:TrancheBLoanMember
2014-02-27
2014-02-28
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:TrancheBLoanMembermnkd:TwoThousandNineteenNotesMembermnkd:Scenario2Member
2014-02-27
2014-02-28
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:TrancheBLoanMembermnkd:TwoThousandNineteenNotesMembermnkd:Scenario1Member
2014-02-27
2014-02-28
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:TrancheBMembermnkd:TwoThousandNineteenNotesMembermnkd:Scenario2Member
2014-02-27
2014-02-28
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:TrancheBMembermnkd:TwoThousandNineteenNotesMembermnkd:Scenario1Member
2014-02-27
2014-02-28
0000899460
mnkd:SeniorConvertibleNotesDueTwoThousandFifteenMember
2010-08-17
2010-08-18
0000899460
mnkd:FurnitureFixturesAndOfficeEquipmentMember
2013-12-31
0000899460
mnkd:ComputerEquipmentAndSoftwareMember
2013-12-31
0000899460
us-gaap:LeaseholdImprovementsMember
2013-12-31
0000899460
us-gaap:LandMember
2013-12-31
0000899460
us-gaap:BuildingMember
2013-12-31
0000899460
us-gaap:MachineryAndEquipmentMember
2013-12-31
0000899460
us-gaap:ConstructionInProgressMember
2013-12-31
0000899460
us-gaap:BuildingImprovementsMember
2013-12-31
0000899460
mnkd:TwoThousandNineteenNotesMember
2013-12-31
0000899460
mnkd:SeniorConvertibleNotesDueTwoThousandFifteenMember
2013-12-31
0000899460
2013-12-31
0000899460
2012-12-31
0000899460
mnkd:FurnitureFixturesAndOfficeEquipmentMember
2014-03-31
0000899460
mnkd:ComputerEquipmentAndSoftwareMember
2014-03-31
0000899460
us-gaap:LeaseholdImprovementsMember
2014-03-31
0000899460
us-gaap:LandMember
2014-03-31
0000899460
us-gaap:BuildingMember
2014-03-31
0000899460
us-gaap:MachineryAndEquipmentMember
2014-03-31
0000899460
us-gaap:ConstructionInProgressMember
2014-03-31
0000899460
us-gaap:BuildingImprovementsMember
2014-03-31
0000899460
mnkd:MilestoneRightsLiabilityMember
2014-03-31
0000899460
mnkd:TwoThousandNineteenNotesMember
2014-03-31
0000899460
mnkd:SeniorConvertibleNotesDueTwoThousandFifteenMember
2014-03-31
0000899460
mnkd:PerformanceBasedRestrictedStockUnitsMember
2014-03-31
0000899460
mnkd:PerformanceBasedStockOptionsMember
2014-03-31
0000899460
us-gaap:RestrictedStockUnitsRSUMember
2014-03-31
0000899460
us-gaap:EmployeeStockOptionMember
2014-03-31
0000899460
mnkd:LoanArrangementMemberus-gaap:PrincipalOwnerMember
2014-03-31
0000899460
mnkd:TrancheThreeMember
2014-03-31
0000899460
mnkd:TrancheBMembermnkd:TwoThousandNineteenNotesMemberus-gaap:MaximumMember
2014-03-31
0000899460
mnkd:TrancheBMember
2014-03-31
0000899460
mnkd:TrancheTwoMember
2014-03-31
0000899460
mnkd:TrancheFourMembermnkd:TwoThousandNineteenNotesMember
2014-03-31
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:TwoThousandNineteenNotesMember
2014-03-31
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:FacilityAgreementMembermnkd:TwoThousandNineteenNotesMemberus-gaap:MaximumMember
2014-03-31
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:NotesIssuedInFourEqualTranchesMembermnkd:TwoThousandNineteenNotesMember
2014-03-31
0000899460
2014-03-31
0000899460
2013-03-31
0000899460
mnkd:TwoThousandNineteenNotesMember
2013-07-01
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:MilestoneRightsLiabilityMemberus-gaap:MaximumMember
2013-07-01
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:NotesIssuedInFourEqualTranchesMembermnkd:TwoThousandNineteenNotesMember
2013-06-30
0000899460
mnkd:TrancheBLoanMemberus-gaap:SubsequentEventMember
2014-05-06
0000899460
2014-05-05
0000899460
us-gaap:FairValueInputsLevel3Membermnkd:TwoThousandNineteenNotesMember
2014-02-28
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:TwoThousandNineteenNotesMember
2014-02-28
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:TrancheBLoanMembermnkd:TwoThousandNineteenNotesMember
2014-02-28
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:TrancheBLoanMembermnkd:TwoThousandNineteenNotesMembermnkd:CollaborationAgreementWithThirdPartyMember
2014-02-28
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:TrancheBLoanMembermnkd:TwoThousandNineteenNotesMembermnkd:Scenario2Member
2014-02-28
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:TrancheBLoanMembermnkd:TwoThousandNineteenNotesMembermnkd:Scenario1Member
2014-02-28
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:TrancheBMembermnkd:TwoThousandNineteenNotesMembermnkd:Scenario2Member
2014-02-28
0000899460
mnkd:DeerfieldManagementCompanyLpMembermnkd:TrancheBMembermnkd:TwoThousandNineteenNotesMembermnkd:Scenario1Member
2014-02-28
0000899460
mnkd:SeniorConvertibleNotesDueTwoThousandFifteenMember
2010-08-18
iso4217:USD
shares
pure
iso4217:USD
shares
utr:D
mnkd:Tranche